Stock QGEN QIAGEN N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Qiagen N.V.

Equities

QGEN

NL0015001WM6

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
41.65 USD +1.39% Intraday chart for Qiagen N.V. +4.12% -6.98%
Apr. 24 QIAGEN N.V. Announces Launch of QIAseq xHYB Mycobacterium Biotechnology Panel for Research Use CI
Apr. 22 European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 7,655 12,018 12,618 11,355 9,910 9,220 - -
Enterprise Value (EV) 1 8,608 13,226 13,495 12,529 10,362 9,520 8,939 8,214
P/E ratio -188 x 34.5 x 25.1 x 27.1 x 30.3 x 23.5 x 21 x 18.9 x
Yield - - - - - - - -
Capitalization / Revenue 5.02 x 6.43 x 5.6 x 5.3 x 5.04 x 4.59 x 4.3 x 4.02 x
EV / Revenue 5.64 x 7.07 x 5.99 x 5.85 x 5.27 x 4.74 x 4.17 x 3.58 x
EV / EBITDA 15.6 x 17.7 x 15.3 x 15.9 x 15.7 x 13.4 x 11.3 x 9.49 x
EV / FCF 40.4 x 40.7 x 30 x 21.4 x 33.5 x 21.3 x 18.1 x 17 x
FCF Yield 2.47% 2.46% 3.33% 4.68% 2.99% 4.69% 5.54% 5.89%
Price to Book 3.08 x 4.31 x 4.08 x 3.28 x 2.71 x 2.35 x 2.12 x 1.94 x
Nbr of stocks (in thousands) 219,691 220,581 220,214 220,869 221,337 221,357 - -
Reference price 2 34.85 54.48 57.30 51.41 44.77 41.65 41.65 41.65
Announcement Date 2/4/20 2/9/21 2/8/22 2/10/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,526 1,870 2,252 2,142 1,965 2,010 2,144 2,296
EBITDA 1 551.8 747.8 884.2 789.7 659 709.7 790.4 865.9
EBIT 1 421.8 626.8 755 656.3 528.6 565.9 618.2 675.4
Operating Margin 27.63% 33.51% 33.53% 30.65% 26.9% 28.15% 28.83% 29.42%
Earnings before Tax (EBT) 1 -77.78 439.5 625.8 512.6 429.8 498.1 566.4 625.7
Net income 1 -41.46 359.2 512.6 423.2 341.3 398.2 442.4 497.2
Net margin -2.72% 19.2% 22.77% 19.76% 17.37% 19.81% 20.63% 21.66%
EPS 2 -0.1856 1.577 2.278 1.897 1.480 1.774 1.980 2.209
Free Cash Flow 1 212.9 325 449.1 586 309.7 446.7 495.1 483.9
FCF margin 13.95% 17.38% 19.95% 27.37% 15.76% 22.22% 23.09% 21.07%
FCF Conversion (EBITDA) 38.58% 43.46% 50.79% 74.21% 47% 62.94% 62.64% 55.88%
FCF Conversion (Net income) - 90.49% 87.61% 138.47% 90.75% 112.16% 111.93% 97.31%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/4/20 2/9/21 2/8/22 2/10/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 535 582 628.4 516 500 498 485.4 494.9 475.9 509.2 457 501.1 505.6 540.3 489.1
EBITDA 1 197 231.6 266.4 178.7 175.9 168.6 157.6 168 158.2 175.3 150.4 174.2 178 197.9 168.4
EBIT 1 164.6 199.3 231.6 146.2 143.5 134.9 124.2 135.6 126.4 142.4 117.2 139.2 142.5 160.8 126.9
Operating Margin 30.77% 34.24% 36.86% 28.33% 28.7% 27.09% 25.59% 27.4% 26.56% 27.97% 25.66% 27.78% 28.19% 29.76% 25.94%
Earnings before Tax (EBT) 151.5 - - - 95.72 - - - - - - - - - -
Net income 1 133.1 129.2 155.3 96.66 82.39 88.84 85.04 80.79 77.82 97.66 76.26 95.86 100.3 113.7 83.97
Net margin 24.89% 22.2% 24.72% 18.73% 16.48% 17.84% 17.52% 16.33% 16.35% 19.18% 16.69% 19.13% 19.84% 21.04% 17.17%
EPS 2 0.5876 0.5773 0.6907 0.4330 0.3711 0.4021 0.3814 0.3608 0.3505 0.4200 0.3368 0.4294 0.4510 0.5104 0.3775
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 11/3/21 2/8/22 4/27/22 7/26/22 11/7/22 2/10/23 5/3/23 8/8/23 10/30/23 2/6/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 953 1,208 876 1,174 452 300 - -
Net Cash position 1 - - - - - - 280 1,005
Leverage (Debt/EBITDA) 1.727 x 1.615 x 0.9912 x 1.486 x 0.6859 x 0.4231 x - -
Free Cash Flow 1 213 325 449 586 310 447 495 484
ROE (net income / shareholders' equity) 12.9% 18.9% 17.4% 12.9% 4.69% 11.8% 12% 12.1%
ROA (Net income/ Total Assets) 6.06% 9.02% 8.53% 6.81% 2.75% 7.5% 7.91% 8.07%
Assets 1 -684.1 3,982 6,008 6,217 12,403 5,310 5,594 6,160
Book Value Per Share 2 11.30 12.70 14.10 15.70 16.50 17.80 19.70 21.50
Cash Flow per Share 2 1.470 2.020 2.840 3.200 1.990 2.740 2.850 3.060
Capex 1 118 133 190 129 150 154 169 183
Capex / Sales 7.73% 7.1% 8.43% 6.03% 7.62% 7.69% 7.9% 7.97%
Announcement Date 2/4/20 2/9/21 2/8/22 2/10/23 2/6/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Qiagen N.V.

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
41.65 USD
Average target price
50.75 USD
Spread / Average Target
+21.86%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
QIAGEN N.V. Stock Qiagen N.V.
-6.98% 9.22B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. QGEN Stock
  4. Financials Qiagen N.V.